Table 3.
Sensitivity and specificity of HPV16 serology defining HPV16 tumor status by concordant HPV16 DNA and HPV16 RNA test results. Sensitivity and specificity were calculated among the: a) retrieved OPC tumors with prior clinical HPV testing and concordant HPV16 DNA/RNA results (N=52) and b) all retrieved OPC tumors regardless of prior clinical HPV testing with concordant HPV16 DNA/RNA results (N=64).
| HPV16 Tumor Status | ||||
|---|---|---|---|---|
|
|
||||
| HPV Serology | HPV16-OPC1 | HPV16-Negative2 | Sensitivity (95% CI) | Specificity (95% CI) |
| Retrieved OPC tumors with prior clinical HPV testing | ||||
| HPV16E6 | N (%) | N (%) | ||
| Seropositive | 34 (94.4) | 1 (6.2) | 94.4% (81.3%–99.3%) | 93.8% (69.8%–99.8%) |
| Seronegative | 2 (5.6) | 15 (93.8) | ||
| Retrieved OPC tumors regardless of prior clinical HPV testing | ||||
| HPV16E6 | N (%) | N (%) | ||
| Seropositive | 42 (93.3) | 1 (5.3) | 93.3% (81.7%–98.6%) | 94.7% (74.0%–99.9%) |
| Seronegative | 3 (6.7) | 18 (94.7) | ||
1
HPV16 DNA and HPV16 RNA dual positive
2
HPV16 DNA and HPV16 RNA dual negative